[{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"GSK pays $50M for 2 solid tumor cell therapies from Immatics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immatics"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"3B Pharmaceuticals"},{"orgOrder":0,"company":"BioMed X","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioMed X Institute and Merck Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"BioMed X"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Evotec And Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Evotec"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene Acquires Worldwide, Exclusive License Of CD40L-CD28 Costimulatory Switch Receptor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Ariceum Therapeutics"},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Medigene"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Glycotope"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IBM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycotope and Evotec Enter Licensing Agreement to Combine Glycotope Antibodies and Evotec\u2019s Immune Cell Engager Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Glycotope"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.
Under the collaboration, Boehringer will use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.
The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC.
MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.
Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer.
Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumors.
Under the expanded collaboration, the companies will develop the pipeline of molecular glue degraders. The companies will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development platforms.
Evotec has significantly scaled up its activities to develop compounds from BMS’s industry-leading library of cereblon E3 ligase modulators and continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the field of oncology.
The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology. The collaboration leverages Evotec’s integrated discovery and development capabilities and manufacturing optimisation processes.
Merck to support up to six more research groups at the BioMed X Institute in Heidelberg within the next six years in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases).